Conmed (CNMD) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Leerink Partners Downgrades CONMED (CNMD) to Market Perform
July 28, 2016 7:17 AM EDTLeerink Partners downgraded CONMED (NASDAQ: CNMD) from Outperform to Market Perform with a price target of $47.00 (from $56.00).
Analyst Richard Newitter commented, "While we are encouraged by Airseal (Surgiquest) outperformance in the qtr, CNMD's organic revenue growth again missed expectations--on weak US ortho capital... More
